GlassScriptPhysician profile
Marissa Jocola
NPI 1700460169
$3,096.91
in general payments reported to CMS, 2019-2025
19 companies · $639 in 2025
The $639 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.47 · 2022: $1,275 · 2023: $523 · 2024: $627 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $687.91 | 2022-2025 | |
| Nevro Corp. | $661.99 | 2022-2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $398.44 | 2022 | |
| Globus Medical, INC. | $295.77 | 2025 | Senza, Vyrsa V1 |
| Saluda Medical Americas, INC. | $167.47 | 2025 | Evoke |
| Boston Scientific Corporation | $163.08 | 2022 | |
| Collegium Pharmaceutical, INC. | $150.52 | 2023-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $123.28 | 2021-2025 | Ztlido |
| Medtronic, INC. | $97.40 | 2022-2023 | Intellis Adaptivestim |
| Pfizer INC. | $67.88 | 2023-2025 | |
| Allergan, INC. | $64.82 | 2022 | |
| Spr Therapeutics, INC | $48.41 | 2024-2025 | Sprint Pns System |
| Bioventus LLC | $48.17 | 2022-2023 | Supartz Fx Sodium Hyaluronate |
| Impel Pharmaceuticals INC. | $36.74 | 2023 | Trudhesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.10 | 2024 | Relistor |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $16.39 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.07 | 2021 | |
| Fidia Pharma USA INC. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Jocola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.